This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Dec 15;314(23):2511-3.

doi: 10.1001/jama.2015.16701.

Alternating Electric Fields for the Treatment of Glioblastoma

John H Sampson¹

Affiliations

PMID: 26670969
DOI: 10.1001/jama.2015.16701

Editorial

Alternating Electric Fields for the Treatment of Glioblastoma

John H Sampson. JAMA. 2015.

. 2015 Dec 15;314(23):2511-3.

doi: 10.1001/jama.2015.16701.

Author

John H Sampson¹

Affiliation

¹ Department of Neurosurgery, Duke University, Durham, North Carolina.

PMID: 26670969
DOI: 10.1001/jama.2015.16701

No abstract available

PubMed Disclaimer

Comment on

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Stupp R, et al. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669. JAMA. 2015. PMID: 26670971 Clinical Trial.

Similar articles

Treatment for Patients With Newly Diagnosed Glioblastoma.
Chamberlain MC. Chamberlain MC. JAMA. 2016 Jun 7;315(21):2348. doi: 10.1001/jama.2016.1844. JAMA. 2016. PMID: 27272590 No abstract available.
Treatment for Patients With Newly Diagnosed Glioblastoma--Reply.
Stupp R, Toms SA, Kesari S. Stupp R, et al. JAMA. 2016 Jun 7;315(21):2348-9. doi: 10.1001/jama.2016.1847. JAMA. 2016. PMID: 27272591 No abstract available.
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Stupp R, et al. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669. JAMA. 2015. PMID: 26670971 Clinical Trial.
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P, Zhu JJ. Zhu P, et al. Chin Clin Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. Chin Clin Oncol. 2017. PMID: 28841803 Review.
Potential usefulness of radiosensitizers in glioblastoma.
Harasaki Y, Waziri A. Harasaki Y, et al. Neurosurg Clin N Am. 2012 Jul;23(3):429-37. doi: 10.1016/j.nec.2012.04.005. Epub 2012 Jun 5. Neurosurg Clin N Am. 2012. PMID: 22748655 Review.

See all similar articles

Cited by

Interleukin 6 and cancer resistance in glioblastoma multiforme.
Detchou D, Barrie U. Detchou D, et al. Neurosurg Rev. 2024 Sep 5;47(1):541. doi: 10.1007/s10143-024-02783-5. Neurosurg Rev. 2024. PMID: 39231832 Review.
Enhancing glioblastoma treatment through the integration of tumor-treating fields.
Szklener K, Bilski M, Nieoczym K, Mańdziuk D, Mańdziuk S. Szklener K, et al. Front Oncol. 2023 Oct 17;13:1274587. doi: 10.3389/fonc.2023.1274587. eCollection 2023. Front Oncol. 2023. PMID: 37916157 Free PMC article. Review.
Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.
Regev O, Merkin V, Blumenthal DT, Melamed I, Kaisman-Elbaz T. Regev O, et al. Neurooncol Pract. 2021 Apr 20;8(4):426-440. doi: 10.1093/nop/npab026. eCollection 2021 Aug. Neurooncol Pract. 2021. PMID: 34277021 Free PMC article. Review.
Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.
Liu Z, Wang H, Jia Y, Wang J, Wang Y, Bian L, Liu B, Lian X, Zhang B, Ren Z, Zhang W, Dai W, Gao Y. Liu Z, et al. Cancer Med. 2021 Aug;10(15):5218-5234. doi: 10.1002/cam4.3954. Epub 2021 Jul 15. Cancer Med. 2021. PMID: 34264013 Free PMC article.
The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.
Tian L, Zhou H, Wang G, Wang WY, Li Y, Xue X. Tian L, et al. PeerJ. 2021 May 14;9:e11422. doi: 10.7717/peerj.11422. eCollection 2021. PeerJ. 2021. PMID: 34040895 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information